Bone Drug Could Help Prevent The Spread Of Breast Cancer

Main Category: Breast Cancer
Also Included In: Clinical Trials / Drug Trials
Article Date: 17 May 2008 - 1:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Maintaining bone density could be a key to decreasing the spread of cancer in women with locally advanced breast cancer, according to research at Washington University School of Medicine in St. Louis.

Bones are common sites for the spread, or metastasis, of breast cancer. Scientists here found that women treated for stage II/III breast cancer who also received a bone strengthening drug were less likely to have breast tumor cells growing in their bones after three months. The bone-strengthening drug used was zoledronic acid, a drug that decreases bone turnover and reduces bone fractures in patients with osteoporosis.

The findings will be reported June 3 at 11 a.m. CT at the 2008 American Society of Clinical Oncology Annual Meeting in Chicago.

"Tumor cells are continually being released from the primary tumor," says lead author Rebecca Aft, M.D., Ph.D., associate professor of surgery, faculty member of the Siteman Cancer Center and a Washington University breast surgeon at Barnes Jewish Hospital. "It is thought that the bone marrow harbors these cells and that these cells are likely to evolve into metastatic disease. We think that zoledronic acid changes the bone marrow so that cancer cells are unable to lodge there."

The researchers randomly assigned 120 women being treated for clinical stage II/III breast cancer to receive 4 milligrams of zoledronic acid intravenously every three weeks for one year, starting with their first cycle of chemotherapy, or to receive no zoledronic acid. Stage II/III cancer means the primary tumor has spread into lymph nodes or other areas near the breast.

At the time of diagnosis, none of the patients had evidence of metastatic disease on computed tomography (CT) and/or positron emission tomography (PET) scans. But bone marrow samples showed that about 40 percent of the patients had detectable breast tumor cells in the bone marrow.

Prior research has shown that women with even minuscule clusters of breast tumor cells called micrometastases in their bone marrow at the time of their diagnosis have an increased risk of developing large metastatic tumors later.

The researchers took bone marrow samples again three months and one year after treatment began. Only 23 percent of women who got zoledronic acid had tumor cells after three months compared to 36 percent of those who didn't get the drug. This result did not reach statistical significance.

Of women who started with no tumor cells in their bone marrow, 88 percent remained free of tumor cells in their bone marrow if they got zoledronic acid, compared to 70 percent of those who did not receive the drug. This result approached statistical significance. The one-year results are not yet available.

Aft says that women who receive chemotherapy for breast cancer have increased rates of bone turnover, which can release growth factors and produce a favorable environment for cancer cells. The suppression of bone turnover by zoledronic acid or other bisphosphonate drugs could make bones less friendly surroundings for cancer.

"We found that patients who are negative for tumor cells in bone marrow have a very good chance of staying negative if they take zoledronic acid," Aft says. "If longer follow up shows that women without tumor cells in their bones do not go on to develop metastatic disease, then it would be reasonable to say that bisphosphonates will likely benefit women with locally advanced breast cancer."

Aft R, Ylagan L, Watson M, Chavez-MacGregor M, Trinkaus K, Zhai J, Naughton M, Weilbaecher K. Effect of zoledronic acid on bone marrow micrometastases in women undergoing neoadjuvant chemotherapy for breast cancer. 2008 American Society of Clinical Oncology Annual Meeting, May 30 - June 2, 2008.

Funding from Novartis and Pfizer Inc. supported this research.

Washington University School of Medicine's 2,100 employed and volunteer faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Children's hospitals. The School of Medicine is one of the leading medical research, teaching and patient care institutions in the nation, currently ranked third in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Children's hospitals, the School of Medicine is linked to BJC HealthCare.

Siteman Cancer Center is the only federally designated Comprehensive Cancer Center within a 240-mile radius of St. Louis. Siteman Cancer Center is composed of the combined cancer research and treatment programs of Barnes-Jewish Hospital and Washington University School of Medicine. Siteman has satellite locations in West County and St. Peters, in addition to its full-service facility at Washington University Medical Center on South Kingshighway.

Washington University in St. Louis
One Brookings Dr., Campus Box 1070
St. Louis, MO 63130
United States
http://www.wustl.edu